You are receiving this message as a subscriber to the FDA HIV/AIDS electronic list serve. The purpose of the list serve is to relay important information about HIV/AIDS-related products and issues, including product approvals, significant labeling changes, safety warnings, notices of upcoming public meetings and alerts to proposed regulatory guidances for comment.

To UNSUBSCRIBE from this list, or change your e-mail address, please go to http://list.nih.gov/cgi-bin/wa?SUBED1=fda-hiv-aids&A=1

Please do not reply to this message.
_______________________________________________

The "Public Health Service Task Force Recommendations for Use of Antiretroviral Drugs in Pregnant HIV-1-Infected Women for Maternal Health and Interventions to Reduce Perinatal HIV-1 Transmission in the United States" have been revised to include:

Updates to Clinical Scenario #3. The new information discusses a 3 to 7 day "tail" of postpartum maternal ZDV/3TC following single dose maternal/infant nevirapine; this "tail" may reduce the risk of nevirapine resistance.

• Updated information on the role of cesarean delivery in preventing mother-to-child transmission of HIV.
• An updated Supplement: Safety and Toxicity of Individual Antiretroviral Agents in Pregnancy, including a new section on tipranavir.
• A Perinatal Antiretroviral Guidelines Working Group Conflict of Interest Disclosure (Appendix).
  

Updated information appears highlighted in yellow.

You can download the updated guidelines, or request to receive them by e-mail or hard copy from the AIDSinfo Web site: http://www.aidsinfo.nih.gov/guidelines/default_db2.asp?id=66.

The AIDSinfo website is also a useful source of other information related to HIV/AIDS, including other treatment and prevention guidelines, downloadable databases for PDAs (Personal Digital Assistants), fact sheets, and HIV/AIDS-related clinical trials information.

Richard Klein
HIV/AIDS Program Director
Office of Special Health Issues
Food and Drug Administration

An archive of past list serve announcements is available on the FDA web site at http://www.fda.gov/oashi/aids/listserve/archive.html